Researchers at the University of Virginia School of Medicine have successfully reversed a severe form of genetic epilepsy in mice using a next-generation gene-editing technique. The study, published in the journal Science Advances, targeted mutations in the SCN1A gene, a known cause of Dravet syndrome, a treatment-resistant form of childhood epilepsy.
The team employed an advanced, high-fidelity version of the CRISPR-Cas9 gene-editing tool to correct the mutation in the brains of adolescent mice. Following treatment, the mice experienced a dramatic reduction in seizures and improved survival rates, with many reaching a normal lifespan. The correction also normalized brain activity and addressed associated symptoms like hyperactivity and cognitive deficits.
Senior author Manoj K. Patel emphasized the significance of treating adolescent mice, as it mirrors a potential clinical scenario for older children diagnosed with the condition. The research demonstrates a proof-of-concept that gene editing can effectively intervene after disease onset, not just preventively.
While the results are promising, the scientists caution that extensive further research is required to ensure safety and efficacy before any human trials can be considered. The study represents a critical step toward developing a one-time, durable treatment for severe genetic epilepsies that currently have limited therapeutic options.
